Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -116.42% is 13% above its 5-year average of -134.00%, near the high end of its 5-year range (-502.60%–13.29%).
As of the fiscal period ended Tuesday, June 30, 2026. 39.09% above its 12-month average of -191.14%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -116.42%.
RETURN ON EQUITY (ROE)
-116.42%
RETURN ON EQUITY (ROE) AVG TTM
-191.14%
RETURN ON EQUITY (ROE) AVG 3Y
-151.96%
RETURN ON EQUITY (ROE) AVG 5Y
-134.00%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+39.09%
CURRENT VS 3Y AVG
+23.38%
CURRENT VS 5Y AVG
+13.11%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-177.13%
vs the sector median at left
Precision BioSciences, Inc.
Market Cap
$171.13M
Return on Equity (ROE)
-116.42%
TTM Avg
-191.14%
3Y Avg
-151.96%
5Y Avg
-134.00%
Market Cap
$172.42M
Return on Equity (ROE)
-31.32%
TTM Avg
4.38%
3Y Avg
4.09%
5Y Avg
11.26%
Market Cap
$169.53M
Return on Equity (ROE)
-19.01%
TTM Avg
-54.50%
3Y Avg
-75.60%
5Y Avg
-59.28%
Market Cap
$168.92M
Return on Equity (ROE)
-56.61%
TTM Avg
-75.88%
3Y Avg
-88.15%
5Y Avg
-30.55%
Market Cap
$173.76M
Return on Equity (ROE)
-54.27%
TTM Avg
-50.07%
3Y Avg
-62.91%
5Y Avg
-60.87%
Market Cap
$168.10M
Return on Equity (ROE)
-7104.24%
TTM Avg
-166.54%
3Y Avg
-137.65%
5Y Avg
-112.46%
Market Cap
$174.27M
Return on Equity (ROE)
-84.80%
TTM Avg
-85.93%
3Y Avg
-69.58%
5Y Avg
-185.12%
Market Cap
$165.32M
Return on Equity (ROE)
3.51%
TTM Avg
-6.60%
3Y Avg
-9.04%
5Y Avg
-6.71%
Market Cap
$165.27M
Return on Equity (ROE)
-47.36%
TTM Avg
-30.00%
3Y Avg
-33.39%
5Y Avg
-32.72%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Precision BioSciences, Inc. (DTIL) | $171.13M | -116.42% | -191.14% | -151.96% | -134.00% |
| Organogenesis Holdings Inc. (ORGO)vs › | $172.42M | -31.32% | 4.38% | 4.09% | 11.26% |
| Journey Medical Corporation (DERM)vs › | $169.53M | -19.01% | -54.50% | -75.60% | -59.28% |
| MediWound Ltd. (MDWD)vs › | $168.92M | -56.61% | -75.88% | -88.15% | -30.55% |
| ProQR Therapeutics N.V. (PRQR)vs › | $173.76M | -54.27% | -50.07% | -62.91% | -60.87% |
| Cue Biopharma, Inc. (CUE)vs › | $168.10M | -7104.24% | -166.54% | -137.65% | -112.46% |
| Yarrow Bioscience Inc (YARW)vs › | $174.27M | -84.80% | -85.93% | -69.58% | -185.12% |
| OptimizeRx Corp. (OPRX)vs › | $165.32M | 3.51% | -6.60% | -9.04% | -6.71% |
| Nkarta, Inc. (NKTX)vs › | $165.27M | -47.36% | -30.00% | -33.39% | -32.72% |
| Oramed Pharmaceuticals Inc. (ORMP)vs › | $179.26M | 55.08% | 9.52% | -0.62% | -4.34% |
ROE
-116.4%
ROA
-41.9%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -116.42% |
| 2026-03-31 | -57.29% |
| 2025-12-31 | -49.57% |
| 2025-09-30 | -502.60% |
| 2025-06-30 | -229.80% |
| 2025-03-31 | -44.56% |
| 2024-12-31 | 12.71% |
| 2024-09-30 | 13.29% |
| 2024-06-30 | 11.41% |
| 2024-03-31 | -97.27% |
| 2023-12-31 | -370.27% |
| 2023-09-30 | -282.27% |
| 2023-06-30 | -262.79% |
| 2023-03-31 | -270.13% |
| 2022-12-31 | -184.73% |
| 2022-09-30 | -124.96% |
| 2022-06-30 | -90.05% |
| 2022-03-31 | -57.54% |
| 2021-12-31 | -33.57% |
| 2021-09-30 | -31.31% |
| 2021-06-30 | -46.25% |
| 2021-03-31 | -171.46% |
| 2020-12-31 | -245.37% |
| 2020-09-30 | -166.82% |
| 2020-06-30 | -118.22% |
| 2020-03-31 | -76.44% |
| 2019-12-31 | -67.15% |
| 2019-09-30 | -56.10% |
| 2019-06-30 | -43.92% |
| 2019-03-31 | -635.35% |
| 2018-12-31 | -115.21% |
